AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
10 Sep 2019
Small Cap Feast
Huddled Group PLC (HUD:LON), 2.8 | Mercia Asset Management PLC (MERC:LON), 35.0 | IQGeo Group PLC (IQG:LON), 397 | Duke Capital Limited (DUKE:LON), 32.2 | Futura Medical plc (FUM:LON), 35.8 | ANGLE plc (AGL:LON), 12.2 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.3 | Ilika plc (IKA:LON), 28.5 | Zinc Media Group plc (ZIN:LON), 77.5
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
Huddled Group PLC (HUD:LON), 2.8 | Mercia Asset Management PLC (MERC:LON), 35.0 | IQGeo Group PLC (IQG:LON), 397 | Duke Capital Limited (DUKE:LON), 32.2 | Futura Medical plc (FUM:LON), 35.8 | ANGLE plc (AGL:LON), 12.2 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.3 | Ilika plc (IKA:LON), 28.5 | Zinc Media Group plc (ZIN:LON), 77.5
- Published:
10 Sep 2019 -
Author:
Derren Nathan - Pages:
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019